Show simple item record

Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic study

dc.contributor.authorMoffat, Bradford A.en_US
dc.contributor.authorHall, Daniel E.en_US
dc.contributor.authorYoung, John M.en_US
dc.contributor.authorDesmond, Timothy J.en_US
dc.contributor.authorCarter, Julieen_US
dc.contributor.authorPietronigro, Dennisen_US
dc.contributor.authorFrey, Kirk A.en_US
dc.contributor.authorRehemtulla1, Alnawazen_US
dc.contributor.authorRoss, Brian D.en_US
dc.contributor.authorHamstra1, Daniel A.en_US
dc.date.accessioned2006-09-11T16:00:39Z
dc.date.available2006-09-11T16:00:39Z
dc.date.issued2005-07en_US
dc.identifier.citationHamstra1, Daniel A.; Moffat, Bradford A.; Hall, Daniel E.; Young, John M.; Desmond, Timothy J.; Carter, Julie; Pietronigro, Dennis; Frey, Kirk A.; Rehemtulla1, Alnawaz; Ross, Brian D.; (2005). "Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic study." Journal of Neuro-Oncology 73(3): 225-238. <http://hdl.handle.net/2027.42/45396>en_US
dc.identifier.issn0167-594Xen_US
dc.identifier.issn1573-7373en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45396
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15980973&dopt=citationen_US
dc.description.abstractSolvent facilitated perfusion (SFP) has been proposed as a technique to increase the delivery of chemotherapeutic agents to tumors. SFP entails direct injection of the agent into the tumor in a water-miscible organic solvent, and because the solvent moves easily through both aqueous solutions and cellular membranes it drives the penetration of the solubilized anticancer agent throughout the tumor. To test this hypothesis, we compared the pharmacokinetics (PK) of 14 C-labeled 1,3-bis-chlorethyl-1-nitrosourea (BCNU) in intra-cerebral 9L rat gliomas after intravenous (IV) infusion in 90% saline –10% ethanol or direct intratumoral (IT) injection of 14 C-BCNU in 100% ethanol (DTI-015). Treatment with DTI-015 yielded a peak radioactive count (Cmax) for the 14 C label that was 100–1000 fold higher in the tumor than in all other tissues in addition to a concentration in the tumor that was 100-fold higher than that achieved following IV infusion of 14 C-BCNU. Pathologic and auto-radiographic analysis of tissue sections following IT injection of 14 C-BCNU in ethanol into either tumor or normal rat brain revealed both an enhanced local volume of distribution and an increased concentration of BCNU delivered to tumor compared to non-tumor bearing brain. To investigate the mechanism behind the SFP of BCNU to the tumor both dynamic contrast and perfusion MRI were performed on 9L tumors before and after treatment and demonstrated a decrease in tumor perfusion following IT injection of DTI-015. Finally, initial PK of patient blood samples following administration of DTI-015 into relapsed high-grade glioma indicated a 20-fold decrease in systemic exposure to BCNU compared to IV infusion of BCNU providing further evidence for the enhanced therapeutic ratio observed for DTI-015.en_US
dc.format.extent577835 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springeren_US
dc.subject.otherBrain Tumoren_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacokineticsen_US
dc.subject.otherOncologyen_US
dc.subject.otherAnimal Modelen_US
dc.subject.otherBCNUen_US
dc.subject.otherMRIen_US
dc.titleIntratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelOphthalmologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumThe Departments of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Center for Molecular Imaging, The University of Michigan Medical Center, 9403 MSRB III, 1500 East Medical Center Drive, Ann Arbor, MI, 48109-0648, USAen_US
dc.contributor.affiliationumDirect Therapeutics Inc., The University of Michigan Medical Center, Redwood City, CA, USAen_US
dc.contributor.affiliationumThe Departments of Radiology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Departments of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Center for Molecular Imaging, The University of Michigan Medical Center, 9403 MSRB III, 1500 East Medical Center Drive, Ann Arbor, MI, 48109-0648, USAen_US
dc.contributor.affiliationumThe Mental Health Research Institute, The University of Michigan Medical Center, Ann Arbor, MIen_US
dc.contributor.affiliationumThe Departments of Radiology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Departments of Biological Chemistry, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Center for Molecular Imaging, The University of Michigan Medical Center, 9403 MSRB III, 1500 East Medical Center Drive, Ann Arbor, MI, 48109-0648, USAen_US
dc.contributor.affiliationumThe Departments of Radiology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Departments of Neurology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Mental Health Research Institute, The University of Michigan Medical Center, Ann Arbor, MIen_US
dc.contributor.affiliationumDirect Therapeutics Inc., The University of Michigan Medical Center, Redwood City, CA, USAen_US
dc.contributor.affiliationumDirect Therapeutics Inc., The University of Michigan Medical Center, Redwood City, CA, USAen_US
dc.contributor.affiliationumThe Departments of Radiology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Center for Molecular Imaging, The University of Michigan Medical Center, 9403 MSRB III, 1500 East Medical Center Drive, Ann Arbor, MI, 48109-0648, USAen_US
dc.contributor.affiliationumThe Departments of Radiology, The University of Michigan Medical Center, Ann Arbor, MI, USA; The Center for Molecular Imaging, The University of Michigan Medical Center, 9403 MSRB III, 1500 East Medical Center Drive, Ann Arbor, MI, 48109-0648, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid15980973en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45396/1/11060_2004_Article_5675.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s11060-004-5675-2en_US
dc.identifier.sourceJournal of Neuro-Oncologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.